Pharmacological blockade of Bcl-2, Bcl-xL and Bcl-w by the BH3 mimetic ABT-737 has only minor impact on tumour development in p53-deficient mice

Apoptosis of leukocytes triggered by acute DNA damage promotes lymphoma formation

(2010) V. Labi et al.   GENES & DEVELOPMENT

Apoptosis-promoted tumorigenesis:  -irradiation-induced thymic lymphomagenesis requires Puma-driven leukocyte death

(2010) E. M. Michalak et al.   GENES & DEVELOPMENT

Cell Death

(2009) Richard S. Hotchkiss et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic

(2008) Mark S. Cragg et al.   JOURNAL OF CLINICAL INVESTIGATION

Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins

(2008) Cheol-Min Park et al.   JOURNAL OF MEDICINAL CHEMISTRY

BCL-2 family antagonists for cancer therapy

(2008) Guillaume Lessene et al.   NATURE REVIEWS DRUG DISCOVERY

In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas

(2008) K. D. Mason et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The BCL-2 protein family: opposing activities that mediate cell death

(2007) Richard J. Youle et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY